Treating Peripheral Neuropathy Pain: An Alternative Approach With Minimal Side Effects.pdf

Carney, M.D., F.A.A.NS., regarding the treatment of peripheral neuropathy pain. It advocates for Electronic Signal Therapy (EST) as a safer and more effective alternative to drug therapy.

Flaws in Conventional Drug Treatment:

Randomized placebo-controlled trials show that drugs like pregabalin only achieve moderate pain reduction (39% vs 15% in the placebo group) and are associated with significant adverse side effects (affecting 38% of patients).
Existing treatments do not relieve pain completely for most patients.

Benefits of Electronic Signal Therapy (EST):

Clinical Evidence: A study of 98 patients showed that EST reduced pain by at least 50% in 63%, with only two minor adverse effects reported.
Mechanism of Action: EST stabilizes cell membranes, combats inflammation, increases cyclic AMP, and improves circulation, addressing the underlying causes of neuropathy.
Case Study: A 34-year-old patient with chemotherapy-induced peripheral neuropathy (CIPN) experienced complete pain relief (VAS from 7/10 to 0/10) after just 17 EST treatments, and successfully ran a marathon three months later.

Observational Evidence Supporting EST:

A study comparing EST to drug therapy found:
83% of patients reduced their pain by at least 50% with EST compared to 62-113% with drugs.
None experienced significant adverse side effects with EST, while 38% of drug users had them.
Up to 73% of patients showed nerve regeneration after EST treatment.

Call to Action:

The author argues that the lack of adequate response to drug therapy for PPN constitutes an unmet need. He urges the pain community, including WIP members, to:

Recognize EST as a promising alternative with strong observational evidence.
* Advocate for further research and wider adoption of EST as the Accepted Standard of Care for PPN.